Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 413 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial completedv413
  2. Study completion date: Mar 31, 2026v412
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 156 of 156 sites
    v411
  4. Start date: Mar 22, 2004 to Mar 25, 2004v410
  5. 3 versions Re-verified since Aug 2, 2022, no change to tracked fieldsv407-v409
Show 43 earlier versionsHide 43 earlier versions
  1. Eligibility criteria shortened, about 4 words
    • Study description shortened, about 1 word
    v406
  2. Re-verified, no change to tracked fieldsv405
  3. Trial status: Active, Not Recruiting to Recruiting
    • Eligibility criteria revised
    • Site details revised at 156 of 156 sites
    v404
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 8100 to confirmed 3885
    • Primary completion date changed from estimate of Jan 1, 2100 to Dec 31, 2004
    • Site details revised at 156 of 156 sites
    v403
  5. Study sites: 154 to 156v402
  6. Study sites revised (154)v401
  7. Study sites: 157 to 154v400
  8. Study sites: 155 to 157
    • Primary completion date: Jan 2100 to Jan 1, 2100
    • Start date: Mar 2004 to Mar 22, 2004
    • Eligibility criteria revised
    v399
  9. Study sites: 153 to 155v398
  10. 3 versions Re-verified since Sep 30, 2015, no change to tracked fieldsv395-v397
  11. Primary endpoints: 2 to 3v394 Show 6 more changesShow less
    • Enrollment target: 6900 to 8100
    • Study sites: 143 to 153
    • Interventions: laboratory biomarker analysis (Other), questionnaire administration (Other) to Laboratory Biomarker Analysis (Other), Questionnaire Administration (Other)
    • Eligibility criteria expanded, about 182 words
    • Study description shortened, about 42 words
    • Study title expanded, about 2 words
  12. 3 versions Re-verified since Aug 21, 2014, no change to tracked fieldsv391-v393
  13. Study sites: 139 to 143v390
  14. Primary completion date: Mar 2005 to Jan 2100v389 Show 5 more changesShow less
    • Study sites: 144 to 139
    • Interventions: cytogenetic analysis (Genetic), mutation analysis (Genetic), polymorphism analysis (Genetic), questionnaire administration (Other) to laboratory biomarker analysis (Other), questionnaire administration (Other)
    • Eligibility criteria shortened, about 137 words
    • Study description shortened, about 68 words
    • Study arms: 0 to 1
  15. Site contacts updated at 1 of 144 sitesv388
  16. Re-verified, no change to tracked fieldsv387
  17. Site contacts updated at 1 of 144 sitesv386
  18. Re-verified, no change to tracked fieldsv385
  19. Study sites revised (144)v384
  20. Re-verified, no change to tracked fieldsv383
  21. Site contacts updated at 1 of 144 sitesv382
  22. Site contacts updated at 1 of 144 sitesv381
  23. Re-verified, no change to tracked fieldsv380
  24. Study sites: 145 to 144v379
  25. Re-verified, no change to tracked fieldsv378
  26. Site contacts updated at 1 of 145 sitesv377
  27. Study sites revised (145)v376
  28. Re-verified, no change to tracked fieldsv375
  29. Study sites: 131 to 145v374
  30. Study sites revised (131)v373
  31. Re-verified, no change to tracked fieldsv372
  32. Study sites revised (131)v371
  33. Re-verified, no change to tracked fieldsv370
  34. Site contacts updated at 1 of 131 sitesv369
  35. Site contacts updated at 1 of 131 sitesv368
  36. Site contacts updated at 1 of 131 sitesv367
  37. Study sites: 129 to 131v366
  38. Study sites: 127 to 129v365
  39. Study sites: 126 to 127v364
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
Trial Details
NCT Number NCT00082745
Lead Sponsor Children's Oncology Group
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Childhood Malignant Neoplasm
Related terms Neoplasms
Enrollment 3,885 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov